Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience. Its principal product is the Intermezzo, a low dose sublingual formulation of zolpidem as a sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. The company has a collaboration agreement with Purdue Pharmaceutical Products, L.P. for the commercialization of Intermezzo in the United States. It is also developing TO-2061, a low dose ondansetron adjunctive therapy, which is in Phase II study for patients with obsessive-compulsive disorder. The company was founded in 2002 and is based in Point Richmond, California.
Symbol:
Current Quote
last: 3.16
bid:
ask:
volume: 139700

as of (GMT): 2013-05-17 20:56:08
*Quotes delayed by 20min.
Stock Exchange / Market : NASDAQ
 Listed 3 consecutive market days. On list 04/18/2012 through 04/23/2012 

3 Month
TSPT 3 Month

6 Month
TSPT 6 Month

1 Year
TSPT 1 Year

Borrow Rates (per share)